v3.25.2
Consolidated Balance Sheets - USD ($)
$ in Millions
Jun. 30, 2025
Dec. 31, 2024
Assets    
Investments, at fair value $ 13,647.8 [1] $ 13,490.4 [2]
Cash and cash equivalents 244.0 278.0
Foreign currency, at fair value (cost—$68 and $17, respectively) 68.0 18.0
Receivable for investments sold and repaid 320.0 186.0
Income receivable 194.0 187.0
Unrealized appreciation on foreign currency forward contracts 0.0 3.0
Deferred financing costs 24.0 26.0
Prepaid expenses and other assets 95.0 31.0
Total assets 14,593.0 14,219.0
Liabilities    
Payable for investments purchased 3.0 2.0
Debt (net of deferred financing costs and discount) [3] 8,041.0 7,351.0
Unrealized depreciation on foreign currency forward contracts 18.0 1.0
Stockholder distributions payable 196.0 0.0
Management fees payable 53.0 53.0
Subordinated income incentive fees payable [4] 36.0 35.0
Administrative services expense payable 6.0 3.0
Interest payable 80.0 108.0
Other accrued expenses and liabilities 19.0 44.0
Total liabilities 8,452.0 7,597.0
Commitments and contingencies [5]
Stockholders’ equity    
Preferred stock, $0.001 par value, 50,000,000 shares authorized, none issued and outstanding 0.0 0.0
Common stock, $0.001 par value, 750,000,000 shares authorized, 280,066,433 and 280,066,433 shares issued and outstanding, respectively 0.0 0.0
Capital in excess of par value 9,284.0 9,284.0
Retained earnings (accumulated deficit) [6] (3,143.0) (2,662.0)
Total stockholders’ equity 6,141.0 6,622.0
Total liabilities and stockholders’ equity $ 14,593.0 $ 14,219.0
Net asset value per share of common stock at period end (in dollars per share) $ 21.93 $ 23.64
Non-controlled/unaffiliated    
Assets    
Investments, at fair value $ 8,930.0 $ 8,573.0
Non-controlled/affiliated    
Assets    
Investments, at fair value 1,110.6 1,140.0
Controlled/affiliated    
Assets    
Investments, at fair value $ 3,606.5 $ 3,776.7
[1] See Note 8 for additional information regarding the fair value of the Company’s financial instruments.
[2] See Note 8 for additional information regarding the fair value of the Company’s financial instruments.
[3] See Note 9 for a discussion of the Company’s financing arrangements.
[4] See Note 2 and 4 for a discussion of the methodology employed by the Company in calculating the subordinated income incentive fees.
[5] See Note 10 for a discussion of the Company’s commitments and contingencies.
[6] See Note 5 for a discussion of the sources of distributions paid by the Company.